EraGen Biosciences, the life science company driving a new era in genetic diagnostics and drug discovery, announced today it has received written validation of its molecular diagnostic technology from the Chinese Center for Disease Control and Prevention in Beijing.
Dr. Irene Hrusovsky, President and CEO of EraGen Biosciences, received the completed Chinese CDC validation report for EraGen's SARS diagnostic test while accompanying Governor Jim Doyle on his recent Wisconsin Trade Mission to China.
EraGen has been assisted by the medical and pharmaceutical consulting group, Medical Quality International, LLC (MQI) in its communications with the Chinese CDC since last year's SARS epidemic when EraGen introduced the first USA manufactured SARS test.
Dr. Fred Ma, President and CEO of MQI, stated, "The EraGen SARS test, one of the few real-time PCR systems in the world, offers unique features that provide high sensitivity and quantitative testing for the SARS virus, while eliminating many traditional difficulties of other RT-PCR methods such as false positive and false negative outcomes as well as no cross reference features."
